Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
verfasst von:
Alessio Cirillo, Daniele Marinelli, Umberto Romeo, Daniela Messineo, Francesca De Felice, Marco De Vincentiis, Valentino Valentini, Silvia Mezi, Filippo Valentini, Luca Vivona, Antonella Chiavassa, Bruna Cerbelli, Daniele Santini, Paolo Bossi, Antonella Polimeni, Paolo Marchetti, Andrea Botticelli
Following publication of the original article [1], the authors noticed that Fig. 4 was a duplicate of Fig. 3.
This correction article consists of the correct Fig. 3 and Fig. 4.
Fig. 3
3A, PFS according to PD-L1 CPS classes; 3B, OS according to PD-L1 CPS classes; 3C, PFS in patients treated with pembrolizumab-based chemoimmunotherapy according to PD-L1 CPS classes; 3D, OS in patients treated with pembrolizumab-based chemoimmunotherapy according to PD-L1 CPS classes; 3E, PFS in patients treated with pembrolizumab monotherapy according to PD-L1 CPS classes; 3F, OS in patients treated with pembrolizumab monotherapy according to PD-L1 CPS classes
Fig. 4
4A, PFS according to ECOG PS classes; 4B, OS according to ECOG PS classes; 4C, PFS in patients treated with pembrolizumab-based chemoimmunotherapy according to ECOG PS classes; 4D, OS in patients treated with pembrolizumab-based chemoimmunotherapy according to ECOG PS classes; 4E, PFS in patients treated with pembrolizumab monotherapy according to ECOG PS classes; 4F, OS in patients treated with pembrolizumab monotherapy according to ECOG PS classes
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
verfasst von
Alessio Cirillo Daniele Marinelli Umberto Romeo Daniela Messineo Francesca De Felice Marco De Vincentiis Valentino Valentini Silvia Mezi Filippo Valentini Luca Vivona Antonella Chiavassa Bruna Cerbelli Daniele Santini Paolo Bossi Antonella Polimeni Paolo Marchetti Andrea Botticelli
Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.
Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.
Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.
Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
